Prime Medicine Q2 net loss narrows on lower expenses

Prime Medicine

06/08/2026 13:15

Overview
US gene editing biotech's Q2 net loss narrowed yr/yr, driven by reduced R&D and G&A costs
Company ended Q2 with $108.8 mln in cash and equivalents, providing runway into 2027
Global clinical programs for Wilson disease and Alpha-1 Antitrypsin Deficiency advancing, initial data expected in 2027

Outlook
Company expects to initiate global Phase 1/2 study of PM577a in 2H 2026, data in 2027
Prime Medicine plans IND/CTA submission for PM647 in 3Q 2026, data in 2027
Company continues FDA engagement for PM359, targeting BLA submission in 1H 2027

Result Drivers
LOWER PERSONNEL COSTS - Co attributed reduced R&D and G&A expenses to workforce reduction and facility cost savings
PIPELINE ADVANCEMENT - Regulatory clearances for PM577a and PM647 enabled global clinical programs, with initial data expected in 2027
REGULATORY PROGRESS - RMAT designation and ongoing FDA engagement for PM359 support expedited review and potential BLA submission in 2027

Company press release: ID:nGNX6tmr6x

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.24
 
Q2 Net Loss
 
$42.11 mln
 
Q2 Income from Operations 
 
-$43.29 mln
 
Q2 Operating Expenses
 
$44.44 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Prime Medicine, Inc. is $7.50, about 143.5% above its August 5 closing price of $3.08

Reuters Recommended Reads
Aug 6 - Intellia Therapeutics Q2 collaboration revenue falls, net loss widens
Aug 3 - Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Aug 5 - Mirum Pharmaceuticals Q2 sales rise, lifts outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)